30 results about "Dihydropyrimidinuria" patented technology

Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

The invention discloses a dihydropyrimidine compound as well as a preparation method and an application thereof, and belongs to the technical field of medicinal chemistry. The structure of the dihydropyrimidine compound provided by the invention is as shown in a formula I in the specification. The preparation method provided by the invention comprises the following steps: carrying out substitution reaction on a compound a and a compound k under the catalysis of alkali to generate a compound b; performing substitution reaction on the compound c and the compound d under an alkaline condition to obtain a compound e; carrying out Mitsunobu reaction on the compound e and f to obtain an intermediate g, and carrying out coupling reaction on the compound g and b to generate a compound h. The invention provides the application of the compound shown in the formula I or salt, solvate, allomer, metabolite, nitric oxide and prodrug thereof in preparation of drugs for treating or preventing P2X3 and/or/P2X2/3 receptor related diseases. The dihydropyrimidine compound disclosed by the invention has a good P2X3 receptor antagonism effect and better safety.

The invention discloses a dihydropyrimidine compound and a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The structure of the dihydropyrimidine compound is as shown in a formula I which is described in the specification. The invention also discloses a preparation method of the dihydropyrimidine compound. The invention provides application of a compound as shown in a formula I or a salt, a solvate, an allomer, a metabolite, nitrogen oxide and a prodrug of the compound in preparation of drugs for treating or preventing P2X3 and/or/P2X2/3 receptor related diseases. The antitussive action time of the compound is obviously prolonged compared with that of a compound in a contrast 1; the inhibitory activity of the compound on P2X3 is superior to that of a compound in a contrast 1 and a positive control drug gefapirant, and the compound almost has no influence on the taste of mice under 10mg/kg intravenous administration, and has a significant statistical difference from that of the positive control drug gefapirant.

The invention relates to an efficient and environment-friendly catalyst. On the mild reaction condition, a method for synthesizing 3,4-dihydropyrimidine-2-one derivative in a one-pot mode is achieved. The method comprises the steps that magnetic nano-particle load SnCl2 is adopted as a catalyst, ethyl alcohol is adopted as a reaction medium, and the three components of aldehyde, an alpha, beta-dicarbonyl compound and urea (thiourea) are condensed in a one-pot mode to obtain the 3,4-dihydropyrimidine-2-one derivative. The magnetic nano-particle load SnCl2 is repeatedly adopted seven times, and the catalytic reaction yield is not lowered obviously. The method is easy to implement, high in yield, short in reaction time, mild in reaction condition and wide in industrial application prospect, and the reusability of a catalytic reaction system is good.

The invention provides an FGFR4 inhibitor which takes 3,4-dihydropyrimidine[4,5-d]pyrimidine-2(1H)-ketone as a mother nucleus and has a covalent structure. According to the embodiment, nine specific compounds are provided, kinase inhibitory activity tests are carried out on the nine compounds, the semi-inhibitory concentration of LX08 on FGFR4 kinase inhibitory activity is only 7 nM, the semi-inhibitory concentration is lower than that of active control FIN-2, and thus LX08 has potential application prospects. Besides, through MALDI-TOF mass spectrum combination experiments on the synthesized compounds, it is found that compounds such as LX01, LX05, LX06, LX07 and LX08 can only be covalently combined with Cys552 in the FGFR4 and cannot be covalently combined with Cys477 in the FGFR4, and LX09 is an FGFR4 inhibitor which can be covalently combined with two cysteine Cys552 and Cys477 in the FGFR4.

The invention discloses a crystal form of a dihydropyrimidine derivative, a preparation method of the crystal form and application of the crystal form in medicines. Specifically, the invention relates to a crystal form A-1 or a crystal form B-1 having a compound represented by a formula (I) or a formula (Ia), a preparation method thereof and an application of the crystal form A-1 or the crystal form B-1 in drugs, and the crystal form A-1 and the crystal form B-1 have high stability under high temperature, high humidity and illumination conditions, and have good pharmacokinetic properties in beagle bodies.

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

The invention discloses an acid addition salt of a dihydropyrimidine derivative and application of the acid addition salt in medicines. The invention particularly relates to a hydrochloride crystal form A, a hydrochloride crystal form B, a sulfate crystal form A, a hydrobromide crystal form A, a phosphate crystal form A, a mesylate crystal form A or a mesylate crystal form B of a compound as shown in a formula (I) or a formula (Ia) and application of the hydrochloride crystal form A, the hydrochloride crystal form B, the sulfate crystal form A, the hydrobromide crystal form A, the phosphate crystal form A, the mesylate crystal form A or the mesylate crystal form B in medicines. The salts provided by the invention have better stability under the conditions of high temperature, high humidity and illumination, and have good pharmacokinetic properties in beagle bodies.

Provided herein are dihydropyrimidine derivatives which are useful in the treatment of HBV infection or HBV-induced diseases, as well as pharmaceutical or medical applications thereof.

A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful in therapy, e.g. for the treatment of cancers, inflammation, autoimmune diseases and graft-versus host diseases (e.g. in transplantation patients). A pharmaceutical composition comprising the compound or its salt and a method for preparing the compound.

The invention provides a dihydropyrimidine-pomalidomide conjugate as well as a preparation method and application thereof. The conjugate has a structure as shown in a formula I. The invention further relates to a preparation method of the compound with the structure as shown in the formula I, a pharmaceutical composition and application of the compound in preparation of anti-HBV drugs.

The invention provides a 3,4-dihydropyrimidine benzonitrile derivative as well as a preparation method and application thereof. The invention discloses a structure of a specific impurity (RRT is an impurity of 1.22) generated in the process of preparing alogliptin benzoate by adopting the route of the original research patent for the first time. The series of impurities have a warning structure, and the content of the impurities in an alogliptin benzoate finished product needs to be detected according to related limits of the genetically toxic impurities. The invention further provides a preparation and purification method of the high-purity compound shown in the formula (A) and a detection method of the content of the impurity compound in the alogliptin benzoate medicine, and therefore quality control over the alogliptin benzoate medicine is achieved.